{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:08:45Z","timestamp":1793419725945,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.esmoop.2024.102942","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T16:25:27Z","timestamp":1710779127000},"page":"102942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Viewing the immune checkpoint VISTA: landscape and outcomes across cancers"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6746-3224","authenticated-orcid":false,"given":"D.","family":"Nishizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"R.","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-312X","authenticated-orcid":false,"given":"J.J.","family":"Adashek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9502-4907","authenticated-orcid":false,"given":"S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nikanjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.P.","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Nesline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pabla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"DePietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4403-0271","authenticated-orcid":false,"given":"J.K.","family":"Sicklick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmoop.2024.102942_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102942_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2024.102942_bib3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102942_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102942_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102942_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102942_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102942_bib8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.4049\/jimmunol.1100660","article-title":"Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models","volume":"187","author":"Flies","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102942_bib9","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"issue":"41","key":"10.1016\/j.esmoop.2024.102942_bib10","doi-asserted-by":"crossref","first-page":"14846","DOI":"10.1073\/pnas.1407447111","article-title":"Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity","volume":"111","author":"Wang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102942_bib11","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41598-017-01411-1","article-title":"Immune-checkpoint protein VISTA critically regulates the IL-23\/IL-17 inflammatory axis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"issue":"6475","key":"10.1016\/j.esmoop.2024.102942_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102942_bib13","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102942_bib14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-018-2169-1","article-title":"VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival","volume":"67","author":"Kuklinski","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102942_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1708065","article-title":"Expression of TIM3\/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1\/PDL1 resistance: implications of immunogram heterogeneity","volume":"9","author":"Kato","year":"2020","journal-title":"Oncoimmunology"},{"issue":"21","key":"10.1016\/j.esmoop.2024.102942_bib16","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102942_bib17","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102942_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102942_bib19","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1073\/pnas.1811067116","article-title":"Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer","volume":"116","author":"Blando","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2024.102942_bib20","first-page":"A238","article-title":"392 Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies","volume":"8","author":"Martinez","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2024.102942_bib21","doi-asserted-by":"crossref","first-page":"TPS3099","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3099","article-title":"Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas","volume":"35","author":"Lee","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2024.102942_bib22","article-title":"HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab","volume":"39","author":"DiMascio","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2024.102942_bib23","first-page":"A193","article-title":"315 W0180 novel anti-VISTA antibody: rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody","volume":"8","author":"Melero","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102942_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jmoldx.2017.10.001","article-title":"Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors","volume":"20","author":"Conroy","year":"2018","journal-title":"J\u00a0Mol Diagn"},{"issue":"19","key":"10.1016\/j.esmoop.2024.102942_bib25","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.3390\/cancers15194789","article-title":"PD-L1 expression by RNA-sequencing in non-small cell lung cancer: concordance with immunohistochemistry and associations with pembrolizumab treatment outcomes","volume":"15","author":"Nesline","year":"2023","journal-title":"Cancers"},{"issue":"50","key":"10.1016\/j.esmoop.2024.102942_bib26","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.18632\/oncotarget.27142","article-title":"Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay","volume":"10","author":"Pabla","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102942_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21037\/atm-20-1076","article-title":"Immune profiling and immunotherapeutic targets in pancreatic cancer","volume":"9","author":"Lenzo","year":"2021","journal-title":"Ann Transl Med"},{"issue":"6349","key":"10.1016\/j.esmoop.2024.102942_bib28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.esmoop.2024.102942_bib29","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.3390\/cancers13133119","article-title":"Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions","volume":"13","author":"Lawlor","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2024.102942_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.oraloncology.2016.04.005","article-title":"Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma","volume":"57","author":"Kondo","year":"2016","journal-title":"Oral Oncol"},{"issue":"7779","key":"10.1016\/j.esmoop.2024.102942_bib31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.esmoop.2024.102942_bib32","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/15384101.2015.1041695","article-title":"Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes","volume":"14","author":"Kurzrock","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.esmoop.2024.102942_bib33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102942_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na\u00efve study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102942_bib35","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2024.102942_bib36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s43018-021-00204-w","article-title":"Missing the target in cancer therapy","volume":"2","author":"Adashek","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.esmoop.2024.102942_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102942_bib38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00262-017-1968-0","article-title":"Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma","volume":"66","author":"Wu","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102942_bib39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41379-021-00901-y","article-title":"Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer","volume":"35","author":"Zong","year":"2022","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102942_bib40","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/1078-0432.CCR-17-2542","article-title":"Spatially resolved and quantitative analysis of VISTA\/PD-1H as a novel immunotherapy target in human non-small cell lung cancer","volume":"24","author":"Villarroel-Espindola","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102942_bib41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00432-020-03463-9","article-title":"Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer","volume":"147","author":"Hou","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102942_bib42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: a mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102942_bib43","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1349-7006.2005.00073.x","article-title":"Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas","volume":"96","author":"Watanabe","year":"2005","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102942_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.it.2017.02.002","article-title":"PSGL-1: a new player in the immune checkpoint landscape","volume":"38","author":"Tinoco","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.esmoop.2024.102942_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636238","article-title":"PSGL-1 immune checkpoint inhibition for CD4(+) T cell cancer immunotherapy","volume":"12","author":"DeRogatis","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102942_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T05:30:46Z","timestamp":1714455046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924007105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2059702924007105"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102942","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viewing the immune checkpoint VISTA: landscape and outcomes across cancers","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102942"}}